Notably, the MSI/ICAM1 pathway is highly expressed in GBM cells, playing an important role in oncogenic resistance, particularly in enhancing tumor invasion, suggesting that MSI1/ICAM1 represents a promising therapeutic target for GBM [22]. This evidence concerns the gene MSI1 and glioblastoma.